A growing number of U.S. employers are reconsidering their pharmacy benefits, with reports indicating that some plan to drop coverage for GLP-1 obesity drugs by 2027 due to increasing costs and usage demands. Major health insurance companies, like Cigna, have already cut coverage for these weight-loss medications for their employees, leading to concerns about accessibility for individuals needing these treatments. The situation raises crucial questions about the affordability of such drugs, not only for private companies but also for public sector employees in states like California. As the debate over GLP-1 coverage intensifies, industry leaders emphasize the need for sustainable and clinically appropriate options to mitigate financial strains while addressing the obesity epidemic.